ARRAY BIOPHARMA INC Insider Trading for February 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARRAY BIOPHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ARRAY BIOPHARMA INC for February 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21 2019 | ARRY | ARRAY BIOPHARMA IN ... | COX CARRIE SMITH | Buy | P | 23.20 | 5,000 | 115,998 | 8,000 | 3 K to 8 K (+166.67 %) | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Option Exercise | M | 10.47 | 25,000 | 261,750 | 0 | ||
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 20.85 | 5,000 | 104,261 | 20,000 | 25 K to 20 K (-20.00 %) | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 20.82 | 5,000 | 104,121 | 25,000 | 30 K to 25 K (-16.67 %) | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Sell | S | 20.51 | 25,000 | 512,693 | 22,720 | 47.7 K to 22.7 K (-52.39 %) | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | LEFKOFF KYLE | Buy | M | 10.47 | 25,000 | 261,750 | 47,720 | 22.7 K to 47.7 K (+110.04 %) | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.63 | 87,500 | 405,125 | 0 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 8.20 | 37,500 | 307,500 | 12,500 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 20.03 | 239,626 | 4,798,511 | 59,994 | 299.6 K to 60 K (-79.98 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.63 | 87,500 | 405,125 | 299,620 | 212.1 K to 299.6 K (+41.25 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 8.20 | 37,500 | 307,500 | 212,120 | 174.6 K to 212.1 K (+21.48 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Option Exercise | M | 3.77 | 85,000 | 320,450 | 404,450 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 22.05 | 85,000 | 1,874,301 | 30,059 | 115.1 K to 30.1 K (-73.88 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Buy | M | 3.77 | 85,000 | 320,450 | 115,059 | 30.1 K to 115.1 K (+282.78 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Haddock Jason | CFO | Sell | S | 20.00 | 11,712 | 234,240 | 30,059 | 41.8 K to 30.1 K (-28.04 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 3.00 | 82,500 | 247,500 | 82,500 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 4.20 | 104,764 | 440,009 | 0 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Sell | S | 21.58 | 187,264 | 4,041,756 | 142,488 | 329.8 K to 142.5 K (-56.79 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 4.20 | 104,764 | 440,009 | 329,752 | 225 K to 329.8 K (+46.56 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 3.00 | 82,500 | 247,500 | 224,988 | 142.5 K to 225 K (+57.90 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 110,000 | 397,100 | 545,820 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 21.64 | 110,000 | 2,380,015 | 238,709 | 348.7 K to 238.7 K (-31.54 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 110,000 | 397,100 | 348,709 | 238.7 K to 348.7 K (+46.08 %) |
| Feb 07 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Option Exercise | M | 8.94 | 40,000 | 357,600 | 363,900 | |
| Feb 07 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Sell | S | 20.00 | 40,000 | 800,000 | 15,021 | 55 K to 15 K (-72.70 %) |
| Feb 07 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 40,000 | 357,600 | 55,021 | 15 K to 55 K (+266.29 %) |
| Feb 07 2019 | ARRY | ARRAY BIOPHARMA IN ... | Oltmans Curtis Gale | General Counsel | Buy | M | 8.94 | 11,100 | 99,234 | 15,021 | 3.9 K to 15 K (+283.09 %) |
| Feb 04 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Option Exercise | M | 4.20 | 95,236 | 399,991 | 104,764 | |
| Feb 04 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Payment of Exercise | F | 18.67 | 21,425 | 400,005 | 142,488 | 163.9 K to 142.5 K (-13.07 %) |
| Feb 04 2019 | ARRY | ARRAY BIOPHARMA IN ... | Saccomano Nicholas A | CSO | Buy | M | 4.20 | 95,236 | 399,991 | 163,913 | 68.7 K to 163.9 K (+138.67 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 7.30 | 113,438 | 828,097 | 113,438 | |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 100,000 | 361,000 | 655,820 | |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.53 | 113,438 | 2,101,541 | 238,709 | 352.1 K to 238.7 K (-32.21 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.30 | 113,438 | 828,097 | 352,147 | 238.7 K to 352.1 K (+47.52 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.25 | 100,000 | 1,825,370 | 238,709 | 338.7 K to 238.7 K (-29.52 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 100,000 | 361,000 | 338,709 | 238.7 K to 338.7 K (+41.89 %) |